drugset / Trial / NCT05304533

A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy Participants

NCT05304533

Phase 1 Completed 45 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effect of co-administration of itraconazole or verapamil on the drug levels of MYK-224 in healthy participants.

Timeline

Start
2022-04-21
Primary completion
2022-11-14
Completion
2022-11-29

Drugs

EvaluationDrugModalityDoseRoute
Subject DELOCAMTEN Small molecule
Subject Itraconazole Small molecule
Subject Verapamil Other / unclassified

Indications

No indication recorded.